http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012529425-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate | 2010-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2012529425-A |
| titleOfInvention | Degarelix manufacturing method |
| abstract | In step-like (stepwise) synthesis of degarelix containing 0.3% by weight or less of 4-([2- (5-hydantoyl)] acetylamino) -phenylalanine analog on (solid support) -NH 2 The step provides an amino acid or peptide solution in which the α-amino group is protected with Fmoc; the support is a peptide between the solution and the amino acid or peptide carbonyl group and (support) -NH 2. Contacting in the presence of a reagent to form a bond; removing the Fmoc by contacting the support with an organic base, particularly piperidine, in an organic solvent. High purity degarelix prepared by the method of the present invention and the use of Fmoc in the synthesis of degarelix are also disclosed. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013540793-A |
| priorityDate | 2009-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.